Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-03-03 DOI:10.1007/s12325-025-03122-w

Steven R. Feldman, Ran Gao, Rhonda L. Bohn, Stephani Gray, Anouk Déruaz-Luyet, Jashin J. Wu

{"title":"Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study","authors":"Steven R. Feldman, Ran Gao, Rhonda L. Bohn, Stephani Gray, Anouk Déruaz-Luyet, Jashin J. Wu","doi":"10.1007/s12325-025-03122-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Palmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.</p><h3>Methods</h3><p>A retrospective cohort study, using healthcare claims data from patients aged ≥ 18 years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM<sup>®</sup> MarketScan<sup>®</sup> Commercial and the Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart databases), was conducted to investigate adherence to and persistence with biologics in patients with PPP.</p><h3>Results</h3><p>Biologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8–100%]; Optum, 61% [8–99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18–64 versus ≥ 65 years (279 [132] vs 258 [140] days).</p><h3>Conclusion</h3><p>In patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 4","pages":"1994 - 2002"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03122-w.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03122-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Palmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.

Methods

A retrospective cohort study, using healthcare claims data from patients aged ≥ 18 years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM^® MarketScan^® Commercial and the Optum^® Clinformatics^® Data Mart databases), was conducted to investigate adherence to and persistence with biologics in patients with PPP.

Results

Biologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8–100%]; Optum, 61% [8–99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18–64 versus ≥ 65 years (279 [132] vs 258 [140] days).

Conclusion

In patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.

查看原文本刊更多论文

掌跖脓疱病患者的生物治疗依从性和持久性：一项真实世界的、基于索赔的研究。

掌跖脓疱病（PPP）是一种虚弱的皮肤状况，其特征是手掌和脚底的脓疱、红斑和鳞屑。银屑病的治疗依从性不理想。方法：一项回顾性队列研究，使用年龄≥18岁的新诊断PPP患者的医疗保健索赔数据（从IBM®MarketScan®Commercial和Optum®Clinformatics®data Mart数据库中选择2016年10月1日至2020年3月31日），调查PPP患者对生物制剂的依从性和持久性。结果：有114/840（13.6%）名MarketScan患者和76/750（10.1%）名Optum患者使用了生物制剂。平均覆盖天数比例(PDC；范围)在数据库之间相似(MarketScan, 66% [8-100%]；Optum, 61%[8-99%])，良好的依从性（≥80% PDC）很少(MarketScan, 42.1%；,为联合健康集团34.2%)。MarketScan的平均（标准差）持续时间稍长（283[121]天），而Optum为275[133]天。年龄之间的平均（范围）依从性相似，尽管18-64岁的患者比≥65岁的患者持续时间更长（279[132]对258[140]天）。结论：PPP患者对生物制剂的依从性较差，且持续时间不同；理解和解决这些观察结果背后的原因可能会改善治疗结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.